Occlutech to close 15 million Euro investment

Aug 24 2011NewsGuard 100/100 Score

Occlutech, a leading European developer of medical implants treating structural heart disease such as PFO, ASD and LAA today announced the closing of a 15 million Euro investment into Occlutech. The investment was lead by Hong Kong based Interlink Investments Ltd. and subscribed by investors as well as Occlutech distribution partners from Japan, Switzerland, Ireland, Austria and Turkey.

Tor Peters, CEO, said in a statement; "This investment will allow us to accelerate our R&D and bringing new, relevant products to the market in the near future. In addition we expect substantial payments by AGA-St.Jude as a result of litigation initiated by AGA in 2006 and culminating in a win for Occlutech in the German Supreme Court in 2011. The additional funding will allow us to aggressively respond to any new, similar litigation initiated in an attempt to divert our attention and resources from creating relevant products that support our customers in their quest to improving and saving patient lives."  

SOURCE Occlutech

Posted in: Business / Finance

Tags: , , ,

Comments (0)

Suggested Reading

The crucial role of sleep in heart healing
NYU Langone Health sets benchmark for heart attack survival rates
UCLA researchers identify key protein in heart healing after attack
Low-level arsenic exposure in water linked to increased heart disease risk
Heart failure mortality declines in Sweden over two decades
Elevated cytokines found in the blood of long COVID sufferers explain heart problems
Cardiac damage framework may identify patients who could benefit from earlier TAVR
Vitiligo linked to increased risk of heart disease and stroke, study finds

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment
(Logout)
Post

Newsletters you may be interested in

See all Newsletters »

Terms

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.

Provide Feedback

You might also like...
AI-powered ECG model predicts heart disease risk with precision